BCG vaccination in South African HIV-exposed infants--risks and benefits.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed.

1. Early versus late BCG vaccination in HIV-1-exposed infants in Uganda: study protocol for a randomized controlled trial.Trials · 2017
   Trial
2. Delayed BCG vaccination results in minimal alterations in T cell immunogenicity of acellular pertussis and tetanus immunizations in HIV-exposed infants.Vaccine · 2015
   Trial
3. Immunogenicity of BCG in HIV-exposed and non-exposed infants following routine birth or delayed vaccination.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2015
   Trial
4. Delaying BCG vaccination until 8 weeks of age results in robust BCG-specific T-cell responses in HIV-exposed infants.The Journal of infectious diseases · 2015
   Trial
5. Recombinant BCGΔBCG1419c protects outbred mice against M. tuberculosis challenge.Vaccine · 2025
   Article
6. Challenges of Diagnosing Mendelian Susceptibility to Mycobacterial Diseases in South Africa.International journal of molecular sciences · 2023
   Review
7. Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trial.EClinicalMedicine · 2022
   Article
8. HIV-1 Persistence in Children during Suppressive ART.Viruses · 2021
   Review
9. Genome-wide association study of resistance to Mycobacterium tuberculosis infection identifies a locus at 10q26.2 in three distinct populations.PLoS genetics · 2021
   Article
10. COVID-19 and the uniqueness of South Africa.Southern African journal of infectious diseases · 2020
    Article
11. Balancing Trained Immunity with Persistent Immune Activation and the Risk of Simian Immunodeficiency Virus Infection in Infant Macaques Vaccinated with Attenuated Mycobacterium tuberculosis or Mycobacterium bovis BCG Vaccine.Clinical and vaccine immunology : CVI · 2017
    Article
12. Getting to 90-90-90 in paediatric HIV: What is needed?Journal of the International AIDS Society · 2015
    Article
13. Tuberculosis: opportunities and challenges for the 90-90-90 targets in HIV-infected children.Journal of the International AIDS Society · 2015
    Review
14. Rifampin-resistant Mycobacterium bovis BCG-induced disease in HIV-infected infant, Vietnam.Emerging infectious diseases · 2013
    Article
15. In silico analysis and experimental validation of Mycobacterium tuberculosis -specific proteins and peptides of Mycobacterium tuberculosis for immunological diagnosis and vaccine development.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2013
    Review
16. Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects.PloS one · 2013
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

11 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as